Be A Freedom Fighter · Bill Library

HR 10655 — VA Medicinal Cannabis Research Act of 2026

Freedom score: -1 (scale −10 to +10)

Sponsor: Rep. Correa, J. Luis [D-CA-46] · Latest action: Referred to the Subcommittee on Health. (2026-10-14)

Full text on GovInfo (introduced version) · Congress.gov · ← Bill Library index

Findings — 17 highlighted provisions

Each item below is one provision documented in the findings file. The same provision is highlighted in the full text underneath, with its section citation and criterion. Everything else on this page is plain, unreviewed bill text.

  1. Sec. 1 — Short title See in text ↓
  2. Sec. 2(a)(1)–(2) · Government Power — VA Office of Research and Development shall undertake a large-scale retrospective, mixed-methods qualitative/observational study on cannabis exposure and outcomes among enrolled veterans with chronic pain or PTSD. This is research, not approval of prescription cannabis or decriminalization See in text ↓
  3. Sec. 2(a)(3)(A)(i)–(vi) · Government Power — Shall triangulate data sources, compare health outcomes using VA electronic health records and benefits-claim datasets, interview veteran cannabis users, estimate needs, survey veterans treated for specified conditions in preceding five years, and assess Veterans Health and Benefits Administration records for participants. Distinguish observational data collection from patient treatment. The provision does not explicitly say each participant must consent to each records linkage See in text ↓
  4. Sec. 2(a)(3)(B)(i)–(xii) · Government Power — Required comparisons include opioid/benzodiazepine/other drug use, alcohol, substance-use disorders, sleep, osteopathic pain, agitation, life quality, mortality/morbidity, readmissions and emergent conditions See in text ↓
  5. Sec. 2(b)–(d) · Government Power — VA shall start study implementation within 180 days, study for 18 months, and report findings to the two Veterans' Affairs committees within 90 days of completion, including whether necessary criteria to launch trials under §3/§4 can be met See in text ↓
  6. Sec. 3(a)(1) · Government Power — If Secretary reports adequate clinical-trial capacity, Secretary shall start cannabis trials no later than 180 days after that report, using cannabis suitable for investigational use as determined by FDA under 21 U.S.C. §355(i); mandatory trigger is conditional, not an unconditional trial launch See in text ↓
  7. Sec. 3(a)(2)(A)(i)–(xi), (B)(i)–(x) · Government Power — Trials shall assess relevant chronic-pain and PTSD symptoms/outcomes, with specified potential measures including opioid use, sleep, inflammation, depression/anxiety, social function, suicidal ideation and nightmares. §3(a)(3)(A)–(I) permits, but does not require, additional study of pulmonary/cardiovascular issues, named cancers, motor accidents and spasticity See in text ↓
  8. Sec. 3(b)–(c)(1)–(2) · Government Power — VA may continue long-term observation of trial participants; shall study varying forms including whole plant and extracts, plant cultivars of varying THC/CBD ratios; may investigate varying administration routes See in text ↓
  9. Sec. 3(d)(1)–(2) · Government Power — Within 18 months of enactment, VA shall submit trial implementation plan to relevant congressional committees and issue the requests for proposals it determines appropriate. Agency discretion governs RFP necessity See in text ↓
  10. Sec. 3(e)(1)–(2) · Government Power — Secretary may terminate trials if VA cannot meet clinical guidelines or trials pose excessive risk, and may terminate upon final report. Neither clause requires stopping for risks unrelated to the stated standards See in text ↓
  11. Sec. 3(f)(1)–(2) · Government Power — During first five years of trial implementation VA shall report periodically, at least annually, to both committees; shall send final report no later than one year after that five-year period See in text ↓
  12. Sec. 4(a) — Study/trials shall reflect veteran demographics using American Community Survey representation, as determined by latest data See in text ↓
  13. Sec. 4(b)(1)–(2) — VA shall preserve collected datasets and survey results for future research and register the data in the National Library of Medicine's clinical-studies database or successor See in text ↓
  14. Sec. 4(c) — Explicit protective command that study/trial data shall be anonymized and not traceable to an individual patient. This directly mitigates exposure from §2 records/claims linkages, though operational success depends on deidentification practices See in text ↓
  15. Sec. 4(d) — Veterans' eligibility for any other benefit may not be affected by participation in observational study or trials. No new cannabis-use criminal immunity is provided See in text ↓
  16. Sec. 4(e)(1)–(3) · Government Power — Preserves Food, Drug and Cosmetic Act, Public Health Service Act, FDA/HHS authority and existing cannabis regulation; does not waive DEA/FDA barriers or legalize possession See in text ↓
  17. Sec. 5(1)–(2) — “Covered veteran” is an individual enrolled in VA's §1705(a) patient system; “Secretary” is VA Secretary. Administrative definitions only See in text ↓

Full text (introduced version)

38 of 40 text blocks highlighted. Source: GovInfo, fetched cached.

[Congressional Bills 119th Congress] [From the U.S. Government Publishing Office] [H.R. 10655 Introduced in House (IH)] <DOC> 119th CONGRESS 2d Session H. R. 10655 To direct the Secretary of Veterans Affairs to carry out a study and clinical trials on the effects of cannabis on certain health outcomes of veterans with chronic pain and post-traumatic stress disorder, and for other purposes. _______________________________________________________________________ IN THE HOUSE OF REPRESENTATIVES October 1, 2026 Mr. Correa (for himself, Mr. Bergman, Mr. Moulton, Ms. Hoyle of Oregon, and Ms. Titus) introduced the following bill; which was referred to the Committee on Veterans' Affairs _______________________________________________________________________ A BILL To direct the Secretary of Veterans Affairs to carry out a study and clinical trials on the effects of cannabis on certain health outcomes of veterans with chronic pain and post-traumatic stress disorder, and for other purposes. Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

Sec. 1 — Short title

This Act may be cited as the ``VA Medicinal Cannabis Research Act of 2026''.

SEC. 2. DEPARTMENT OF VETERANS AFFAIRS LARGE-SCALE, MIXED METHODS, RETROSPECTIVE QUALITATIVE STUDY ON THE EFFECTS OF CANNABIS ON CERTAIN HEALTH OUTCOMES OF VETERANS WITH CHRONIC PAIN AND POST-TRAUMATIC STRESS DISORDER.

Sec. 2(a)(1)–(2) · Government Power — VA Office of Research and Development shall undertake a large-scale retrospective, mixed-methods qualitative/observational study on cannabis exposure and outcomes among enrolled veterans with chronic pain or PTSD. This is research, not approval of prescription cannabis or decriminalization

Sec. 2(a)(3)(A)(i)–(vi) · Government Power — Shall triangulate data sources, compare health outcomes using VA electronic health records and benefits-claim datasets, interview veteran cannabis users, estimate needs, survey veterans treated for specified conditions in preceding five years, and assess Veterans Health and Benefits Administration records for participants. Distinguish observational data collection from patient treatment. The provision does not explicitly say each participant must consent to each records linkage

Sec. 2(a)(3)(B)(i)–(xii) · Government Power — Required comparisons include opioid/benzodiazepine/other drug use, alcohol, substance-use disorders, sleep, osteopathic pain, agitation, life quality, mortality/morbidity, readmissions and emergent conditions

(a) Study Required.--

Sec. 2(a)(1)–(2) · Government Power — VA Office of Research and Development shall undertake a large-scale retrospective, mixed-methods qualitative/observational study on cannabis exposure and outcomes among enrolled veterans with chronic pain or PTSD. This is research, not approval of prescription cannabis or decriminalization

(1) In general.--The Secretary, through the Office of Research and Development of the Department of Veterans Affairs, shall carry out a large-scale, mixed methods, retrospective, and qualitative study on the effects of cannabis on the health outcomes of covered veterans diagnosed with chronic pain and covered veterans diagnosed with post-traumatic stress disorder.

Sec. 2(a)(1)–(2) · Government Power — VA Office of Research and Development shall undertake a large-scale retrospective, mixed-methods qualitative/observational study on cannabis exposure and outcomes among enrolled veterans with chronic pain or PTSD. This is research, not approval of prescription cannabis or decriminalization

(2) Observational study.--The study required by paragraph (1) shall be conducted as an observational study on the effects of cannabis use on the health of covered veterans.

Sec. 2(a)(3)(A)(i)–(vi) · Government Power — Shall triangulate data sources, compare health outcomes using VA electronic health records and benefits-claim datasets, interview veteran cannabis users, estimate needs, survey veterans treated for specified conditions in preceding five years, and assess Veterans Health and Benefits Administration records for participants. Distinguish observational data collection from patient treatment. The provision does not explicitly say each participant must consent to each records linkage

Sec. 2(a)(3)(B)(i)–(xii) · Government Power — Required comparisons include opioid/benzodiazepine/other drug use, alcohol, substance-use disorders, sleep, osteopathic pain, agitation, life quality, mortality/morbidity, readmissions and emergent conditions

(3) Elements.-- (A) In general.--The study required by paragraph (1) shall-- (i) triangulate a range of data sources; (ii) compare the positive and negative health outcomes of covered veterans who use cannabis, utilizing outcomes that can be measured in an electronic health record of the Department and through data sets of the Department relating to claims for benefits under the laws administered by the Secretary; (iii) elicit the positive and negative outcomes of cannabis use for covered veterans through semi-structured interviews; (iv) estimate current and future health system needs to address positive and negative outcomes of cannabis use for covered veterans; (v) include a qualitative, open-ended survey provided to covered veterans who have sought care from the Department for chronic pain or post-traumatic stress disorder during the five-year period preceding the survey; and (vi) include an assessment of-- (I) all records within the Veterans Health Administration for covered veterans participating in the study; and (II) all records within the Veterans Benefits Administration for covered veterans participating in the study. (B) Health outcomes.--A comparison of health outcomes under subparagraph (A)(ii) shall include an assessment of the following: (i) The reduction or increase in opiate use or dosage. (ii) The reduction or increase in benzodiazepine use or dosage. (iii) The reduction or change in use of other types of medication. (iv) The reduction or increase in alcohol use. (v) The reduction or increase in the prevalence of substance abuse disorders. (vi) Sleep quality. (vii) Osteopathic pain (including pain intensity and pain-related outcomes). (viii) Agitation. (ix) Quality of life. (x) Mortality and morbidity. (xi) Hospital readmissions. (xii) Any newly developed or exacerbated health conditions, including mental health conditions.

Sec. 2(b)–(d) · Government Power — VA shall start study implementation within 180 days, study for 18 months, and report findings to the two Veterans' Affairs committees within 90 days of completion, including whether necessary criteria to launch trials under §3/§4 can be met

(b) Implementation.--Not later than 180 days after the date of the enactment of this Act, the Secretary shall commence the implementation of the study required by subsection (a)(1).

Sec. 2(b)–(d) · Government Power — VA shall start study implementation within 180 days, study for 18 months, and report findings to the two Veterans' Affairs committees within 90 days of completion, including whether necessary criteria to launch trials under §3/§4 can be met

(c) Duration of Study.--The study required by subsection (a)(1) shall be carried out for an 18-month period.

Sec. 2(b)–(d) · Government Power — VA shall start study implementation within 180 days, study for 18 months, and report findings to the two Veterans' Affairs committees within 90 days of completion, including whether necessary criteria to launch trials under §3/§4 can be met

(d) Report.--

Sec. 2(b)–(d) · Government Power — VA shall start study implementation within 180 days, study for 18 months, and report findings to the two Veterans' Affairs committees within 90 days of completion, including whether necessary criteria to launch trials under §3/§4 can be met

(1) In general.--Not later than 90 days after the completion of the study required by subsection (a)(1), the Secretary shall submit to the Committee on Veterans' Affairs of the Senate and the Committee on Veterans' Affairs of the House of Representatives a report on the study.

Sec. 2(b)–(d) · Government Power — VA shall start study implementation within 180 days, study for 18 months, and report findings to the two Veterans' Affairs committees within 90 days of completion, including whether necessary criteria to launch trials under §3/§4 can be met

(2) Ability to conduct clinical trials.--The Secretary shall include in the report required by paragraph (1) an assessment of whether the Secretary is able to meet the criteria necessary to conduct the clinical trials required under section 4, including consideration of subsection (e)(1) of such section.

SEC. 3. DEPARTMENT OF VETERANS AFFAIRS CLINICAL TRIALS ON THE EFFECTS OF CANNABIS ON CERTAIN HEALTH OUTCOMES OF VETERANS WITH CHRONIC PAIN AND POST-TRAUMATIC STRESS DISORDER.

Sec. 3(a)(1) · Government Power — If Secretary reports adequate clinical-trial capacity, Secretary shall start cannabis trials no later than 180 days after that report, using cannabis suitable for investigational use as determined by FDA under 21 U.S.C. §355(i); mandatory trigger is conditional, not an unconditional trial launch

Sec. 3(a)(2)(A)(i)–(xi), (B)(i)–(x) · Government Power — Trials shall assess relevant chronic-pain and PTSD symptoms/outcomes, with specified potential measures including opioid use, sleep, inflammation, depression/anxiety, social function, suicidal ideation and nightmares. §3(a)(3)(A)–(I) permits, but does not require, additional study of pulmonary/cardiovascular issues, named cancers, motor accidents and spasticity

(a) Clinical Trials Required.--

Sec. 3(a)(1) · Government Power — If Secretary reports adequate clinical-trial capacity, Secretary shall start cannabis trials no later than 180 days after that report, using cannabis suitable for investigational use as determined by FDA under 21 U.S.C. §355(i); mandatory trigger is conditional, not an unconditional trial launch

(1) In general.--If the Secretary indicates in the report required by section 2(d) that the Secretary is able to meet the criteria necessary to proceed to clinical trials, commencing not later than 180 days after the submittal of that report, the Secretary shall carry out a series of clinical trials on the effects of cannabis appropriate for investigational use, as determined by the Food and Drug Administration under section 505(i) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(i)), on the health outcomes of covered veterans diagnosed with chronic pain and covered veterans diagnosed with post- traumatic stress disorder.

Sec. 3(a)(2)(A)(i)–(xi), (B)(i)–(x) · Government Power — Trials shall assess relevant chronic-pain and PTSD symptoms/outcomes, with specified potential measures including opioid use, sleep, inflammation, depression/anxiety, social function, suicidal ideation and nightmares. §3(a)(3)(A)–(I) permits, but does not require, additional study of pulmonary/cardiovascular issues, named cancers, motor accidents and spasticity

(2) Considerations.--The clinical trials required by paragraph (1) shall include, as appropriate, an evaluation of key symptoms, clinical outcomes, and conditions associated with chronic pain and post-traumatic stress disorder, which may include-- (A) with respect to covered veterans diagnosed with chronic pain, an evaluation of the effects of the use of cannabis on-- (i) osteopathic pain (including pain intensity and pain-related outcomes); (ii) the reduction or increase in opioid use or dosage; (iii) the reduction or increase in benzodiazepine use or dosage; (iv) the reduction or increase in alcohol use; (v) the reduction or increase in the prevalence of substance use disorders; (vi) inflammation; (vii) sleep quality; (viii) agitation; (ix) quality of life; (x) exacerbated or new mental health conditions; and (xi) suicidal ideation; and (B) with respect to covered veterans diagnosed with post-traumatic stress disorder, an evaluation of the effects of the use of cannabis on-- (i) the symptoms of post-traumatic stress disorder (PTSD) as established by or derived from the clinician administered PTSD scale, the PTSD checklist, the PTSD symptom scale, the post-traumatic diagnostic scale, and other applicable methods of evaluating symptoms of post-traumatic stress disorder; (ii) the reduction or increase in benzodiazepine use or dosage; (iii) the reduction or increase in alcohol use; (iv) the reduction or increase in the prevalence of substance use disorders; (v) mood; (vi) anxiety; (vii) social functioning; (viii) agitation; (ix) suicidal ideation; and (x) sleep quality, including frequency of nightmares and night terrors.
(3) Optional elements.--The clinical trials required by paragraph (1) may include, as appropriate, an evaluation of the effects of the use of cannabis to treat chronic pain and post- traumatic stress disorder on other symptoms, clinical outcomes, and conditions not covered by paragraph (2), which may include-- (A) pulmonary function; (B) cardiovascular events; (C) head, neck, and oral cancer; (D) testicular cancer; (E) ovarian cancer; (F) transitional cell cancer; (G) intestinal inflammation; (H) motor vehicle accidents; or (I) spasticity.

Sec. 3(b)–(c)(1)–(2) · Government Power — VA may continue long-term observation of trial participants; shall study varying forms including whole plant and extracts, plant cultivars of varying THC/CBD ratios; may investigate varying administration routes

(b) Long-Term Observational Study.--The Secretary may carry out a long-term observational study of the participants in the clinical trials required by subsection (a).

Sec. 3(b)–(c)(1)–(2) · Government Power — VA may continue long-term observation of trial participants; shall study varying forms including whole plant and extracts, plant cultivars of varying THC/CBD ratios; may investigate varying administration routes

(c) Type of Cannabis.--

Sec. 3(b)–(c)(1)–(2) · Government Power — VA may continue long-term observation of trial participants; shall study varying forms including whole plant and extracts, plant cultivars of varying THC/CBD ratios; may investigate varying administration routes

(1) In general.--In carrying out the clinical trials required by subsection (a), the Secretary shall study varying forms of cannabis, including whole plant raw material and extracts, and may study varying routes of administration.

Sec. 3(b)–(c)(1)–(2) · Government Power — VA may continue long-term observation of trial participants; shall study varying forms including whole plant and extracts, plant cultivars of varying THC/CBD ratios; may investigate varying administration routes

(2) Plant cultivars.--Of the varying forms of cannabis required under paragraph (1), the Secretary shall study plant cultivars with varying ratios of tetrahydrocannabinol to cannabidiol.

Sec. 3(d)(1)–(2) · Government Power — Within 18 months of enactment, VA shall submit trial implementation plan to relevant congressional committees and issue the requests for proposals it determines appropriate. Agency discretion governs RFP necessity

(d) Implementation.--Not later than 18 months after the date of the enactment of this Act, the Secretary shall--

Sec. 3(d)(1)–(2) · Government Power — Within 18 months of enactment, VA shall submit trial implementation plan to relevant congressional committees and issue the requests for proposals it determines appropriate. Agency discretion governs RFP necessity

(1) develop a plan to implement this section and submit such plan to the Committee on Veterans' Affairs of the Senate and the Committee on Veterans' Affairs of the House of Representatives; and

Sec. 3(d)(1)–(2) · Government Power — Within 18 months of enactment, VA shall submit trial implementation plan to relevant congressional committees and issue the requests for proposals it determines appropriate. Agency discretion governs RFP necessity

(2) issue any requests for proposals the Secretary determines appropriate for such implementation.

Sec. 3(e)(1)–(2) · Government Power — Secretary may terminate trials if VA cannot meet clinical guidelines or trials pose excessive risk, and may terminate upon final report. Neither clause requires stopping for risks unrelated to the stated standards

(e) Termination of Clinical Trials.--

Sec. 3(e)(1)–(2) · Government Power — Secretary may terminate trials if VA cannot meet clinical guidelines or trials pose excessive risk, and may terminate upon final report. Neither clause requires stopping for risks unrelated to the stated standards

(1) Clinical guideline requirements or excessive risk.--The Secretary may terminate the clinical trials required by subsection (a) if the Secretary determines that the Department of Veterans Affairs is unable to meet clinical guideline requirements necessary to conduct such trials or the clinical trials would create excessive risk to participants.

Sec. 3(e)(1)–(2) · Government Power — Secretary may terminate trials if VA cannot meet clinical guidelines or trials pose excessive risk, and may terminate upon final report. Neither clause requires stopping for risks unrelated to the stated standards

(2) Completion upon submittal of final report.--The Secretary may terminate the clinical trials required by subsection (a) upon submittal of the final report required under subsection (f)(2).

Sec. 3(f)(1)–(2) · Government Power — During first five years of trial implementation VA shall report periodically, at least annually, to both committees; shall send final report no later than one year after that five-year period

(f) Reports.--

Sec. 3(f)(1)–(2) · Government Power — During first five years of trial implementation VA shall report periodically, at least annually, to both committees; shall send final report no later than one year after that five-year period

(1) Periodic reports.--During the five-year period beginning on the date of the commencement of clinical trials required by subsection (a), the Secretary shall submit periodically, but not less frequently than annually, to the Committee on Veterans' Affairs of the Senate and the Committee on Veterans' Affairs of the House of Representatives reports on the implementation of this section.

Sec. 3(f)(1)–(2) · Government Power — During first five years of trial implementation VA shall report periodically, at least annually, to both committees; shall send final report no later than one year after that five-year period

(2) Final report.--Not later than one year after the completion of the five-year period specified in paragraph (1), the Secretary shall submit to the Committee on Veterans' Affairs of the Senate and the Committee on Veterans' Affairs of the House of Representatives a final report on the implementation of this section.

SEC. 4. ADMINISTRATION OF STUDY AND CLINICAL TRIALS.

Sec. 4(a) — Study/trials shall reflect veteran demographics using American Community Survey representation, as determined by latest data

(a) Demographic Representation.--In carrying out the study required by section 2 and the clinical trials required by section 3, the Secretary shall ensure representation in such study and trials of demographics that represent the population of veterans in the United States, as determined by the most recently available data from the American Community Survey of the Bureau of the Census.

Sec. 4(b)(1)–(2) — VA shall preserve collected datasets and survey results for future research and register the data in the National Library of Medicine's clinical-studies database or successor

(b) Data Preservation.--The Secretary shall ensure that the study required by section 2 and the clinical trials required by section 3 include a mechanism to ensure--

Sec. 4(b)(1)–(2) — VA shall preserve collected datasets and survey results for future research and register the data in the National Library of Medicine's clinical-studies database or successor

(1) the preservation of all data, including all data sets and survey results, collected or used for purposes of such study and trials in a manner that will facilitate further research; and

Sec. 4(b)(1)–(2) — VA shall preserve collected datasets and survey results for future research and register the data in the National Library of Medicine's clinical-studies database or successor

(2) registration of such data in the database of privately and publicly funded clinical studies maintained by the National Library of Medicine (or successor database).

Sec. 4(c) — Explicit protective command that study/trial data shall be anonymized and not traceable to an individual patient. This directly mitigates exposure from §2 records/claims linkages, though operational success depends on deidentification practices

(c) Anonymous Data.--The Secretary shall ensure that data relating to any study or clinical trial conducted under this Act is anonymized and cannot be traced back to an individual patient.

Sec. 4(d) — Veterans' eligibility for any other benefit may not be affected by participation in observational study or trials. No new cannabis-use criminal immunity is provided

(d) Effect on Other Benefits.--The eligibility or entitlement of a covered veteran to any other benefit under the laws administered by the Secretary or any other provision of law shall not be affected by the participation of the covered veteran in the study under section 2, a clinical trial under section 3(a), or a study under section 3(b).

Sec. 4(e)(1)–(3) · Government Power — Preserves Food, Drug and Cosmetic Act, Public Health Service Act, FDA/HHS authority and existing cannabis regulation; does not waive DEA/FDA barriers or legalize possession

(e) Effect on Other Laws.--Nothing in this Act shall affect or modify--

Sec. 4(e)(1)–(3) · Government Power — Preserves Food, Drug and Cosmetic Act, Public Health Service Act, FDA/HHS authority and existing cannabis regulation; does not waive DEA/FDA barriers or legalize possession

(1) the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.);

Sec. 4(e)(1)–(3) · Government Power — Preserves Food, Drug and Cosmetic Act, Public Health Service Act, FDA/HHS authority and existing cannabis regulation; does not waive DEA/FDA barriers or legalize possession

(2) section 351 of the Public Health Service Act (42 U.S.C. 262); or

Sec. 4(e)(1)–(3) · Government Power — Preserves Food, Drug and Cosmetic Act, Public Health Service Act, FDA/HHS authority and existing cannabis regulation; does not waive DEA/FDA barriers or legalize possession

(3) the authority of the Commissioner of Food and Drugs and the Secretary of Health and Human Services-- (A) under-- (i) the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.); or (ii) section 351 of the Public Health Service Act (42 U.S.C. 262); or (B) to promulgate Federal regulations and guidelines pertaining to cannabidiol, marijuana, or other subject matter addressed in this Act.

SEC. 5. DEFINITIONS.

In this Act:

Sec. 5(1)–(2) — “Covered veteran” is an individual enrolled in VA's §1705(a) patient system; “Secretary” is VA Secretary. Administrative definitions only

(1) The term ``covered veteran'' means a veteran who is enrolled in the patient enrollment system of the Department of Veterans Affairs established and operated under section 1705(a) of title 38, United States Code.

Sec. 5(1)–(2) — “Covered veteran” is an individual enrolled in VA's §1705(a) patient system; “Secretary” is VA Secretary. Administrative definitions only

(2) The term ``Secretary'' means the Secretary of Veterans Affairs. <all>

Findings source: bill-scores-v2-batch40-findings-2026-11-15.md. Highlights come only from that file; no finding, score, or provision was invented for this page.

What you can do

Contact your U.S. Representative and Senators about this bill.

Find your Representative Contact your Senators

Spot an error on this page? Report it.